Why JD, Cisco, and Coherent Dropped
China’s e-commerce giant, JD (JD), posted a 22.4% Y/Y increase in revenue. Yet shares dropped from around $32.50 to as low as around $31.33 on August 14.Investors continue to distrust China-based companies. Optimistic holders mistakenly compare JD to a U.S.-based company like Amazon (AMZN) or eBay (EBAY). They reason that the stock should trade at $90. JD will need to buy more than $1.5 billion out of the $5 billion allocated for share buyback. It also needs to develop its food delivery business model.Cisco Systems (CSCO) posted good Q1 results on August 13. But the stock fell from over $70 to close at $66.20 last week. Its Q1 guidance of up to $14.85 billion is close to consensus. FY 2026 revenue of up to $60.0 billion is above the $56.6 billion consensus estimate.Stock markets are not appreciating CSCO stock. They should ignore the HSBC downgrade, which cited valuation fears.Coherent (COHR) fell by 19% last week after posting results. Investors wanted a stronger first-quarter guidance. Instead, the revenue and earnings expectations are below consensus.Coherent trades at a premium, yet its long-term prospects are strong. Expect a rough one or two quarters of underperformance. Revenue momentum will improve by next year, rewarding patient investors.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


